LL-37
Last reviewed 2026-10-30
Our read Opinion
Published ulcer trials provide human evidence, but active trial status is unverified. FDA moved the nomination to its withdrawn table and still flags safety uncertainties, including nonclinical tumor-related concerns.
- Type
- Investigational (in trials)
- Regulatory status
- Not FDA-approved; no verified marketing authorization
- Compounding status
- Off Category 2, review pending
- FDA-approved indications
- None
- Evidence level
- Small/early human studies
- Routes studied
- —
- WADA
- Verify
- Developer
- —
Claims made by researchers, companies and users. Inclusion does not mean the claim is verified.
- —Claimed to support defense against infections
Human cathelicidin antimicrobial peptide with membrane-disrupting and immune-signaling activities. Its effects on inflammation and tissue repair are context dependent.
No FDA approval or verified foreign marketing authorization. Synthetic LL-37 has been evaluated in randomized topical venous-ulcer trials; these do not establish systemic treatment efficacy.
Statuses change; check the linked primary source.
Momentum Opinion
Watch
0 news items in last 30 days
Topical wound research is more informative than broad antimicrobial marketing claims. It cannot establish safety or benefit for unrelated systemic use.
No news yet for this peptide.
Stronger immune defense, faster recovery from infections, and support for chronic infections or mold illness.
Information only. Not medical advice. Listing a compound is not an endorsement or a recommendation to obtain or use it. Ratings and "Our Take" are editorial opinion. Full disclaimer.